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In the adult central nervous system, two distinct populations of
glial cells expressing the chondroitin sulfate proteoglycan NG2
have been described: bipolar progenitor cells and more differen-
tiated ‘‘synantocytes.’’ These cells have diverse neurological func-
tions, including critical roles in synaptic transmission, repair, and
regeneration. Despite their potential importance, the genetic fac-
tors that regulate NG2 cell development are poorly understood,
and the relationship of synantocytes to the oligodendroglial lin-
eage, in particular, remains controversial. Here, we show that
>90% of embryonic and adult NG2 cells express Olig2, a basic
helix–loop–helix transcription factor required for oligodendrocyte
lineage specification. Analysis of mice lacking Olig function dem-
onstrates a failure of NG2 cell development at embryonic and
perinatal stages that can be rescued by addition of a transgene
containing the human OLIG2 locus. These findings show a general
requirement for Olig function in NG2 cell development and high-
light further roles for Olig transcription factors in neural progenitor
cells.
Cspg4  oligodendrocyte  synantocyte  glia  regeneration
NG2 cells are central nervous system (CNS) glial cells definedby their expression of the chondroitin sulfate proteoglycan,
NG2, which is also known as Cspg4 or AN2 (1–4). A significant
proportion of NG2 cells actively proliferate and indeed have
been characterized as the most prevalent cycling progenitor cell
population in the adult CNS (5, 6). NG2 cells have diverse
functions and participate in oligodendrogenesis (7) and neuro-
genesis (8), as well as the physiologic support of neurons and
synaptic signaling (4, 9). They have also been proposed to play
critical roles in brain repair and regeneration and are the primary
responding neural cell type to CNS injury (10, 11).
Despite their abundance as a progenitor population and
potential importance in maintenance and repair of neurological
function, the developmental ontogeny of NG2 cells remains
controversial (4, 7, 12). Cytologically, they are reportedly a
heterogeneous population, and two distinctive cellular morphol-
ogies have been described: bipolar progenitor cells that resemble
oligodendrocyte progenitors (OLP) (1, 13) and stellate ‘‘synan-
tocytes.’’ Most postnatal NG2 cells are synantocytes, which are
defined by a complex ‘‘differentiated’’ morphologic appearance.
Even so, they lack expression of most differentiated glial cell-
type specific markers (12). Indeed, based on these observations,
several studies have suggested that the majority of postnatal
NG2 synantocytes comprise an independent neuroepithelial
lineage distinct from neurons, astrocytes, and oligodendrocytes
(4, 12, 14), a proposal that has provoked ongoing debate (15, 16).
The genetic pathways, which regulate NG2 cell development,
have yet to be defined, and the question of whether bipolar NG2
cells and synantocytes have fundamentally similar or different
origins is unresolved. Given their early developmental expres-
sion of OLP markers, NG2 cell formation might be regulated by
the same genetic pathways that control oligodendrocyte devel-
opment. During embryogenesis, Olig1 and Olig2 encode basic
helix–loop–helix transcription factor proteins that are required
for development of motor neuron and OLPs (17–19). Although
Olig1 can participate in OLP specification in the developing
brain (19), it is more generally required for maturation of OLPs
to oligodendrocytes in neonates (20) and in repair of demyeli-
nating lesions (21). In the adult brain, Olig2 expression has been
reported in type C cells of the subventricular zone (SVZ) (22).
However, outside of the SVZ in the normal CNS, Olig2 is
expressed in oligodendroglial progenitor cells and mature oli-
godendrocytes (23, 24).
If aspects of NG2 cell development occur independently of
oligodendroglial development, then a testable prediction is that
NG2 cells would be generated in the absence of Olig function. To
evaluate this prediction, we focused on expression and function of
Olig2 in the rodent brain. Our data indicate that Olig2 expression
marks parenchymal NG2 cells, and that Olig gene function is
necessary for NG2 cell development throughout the CNS at ante-
natal stages, including both bipolar progenitor cells (i.e., OLPs) and
synantocytes. Together, our findings provide genetic support for a
unified NG2OLP developmental connection.
Results
More Than 90% of NG2 Cells Express Olig2 in the Brain. We first
determined whether Olig2 expression was limited to a particular
stage of NG2 cell development. To complement our analysis
using existing antibody reagents to Olig2 andNG2, we developed
a monoclonal antibody to Olig2, which specifically recognizes
mouse Olig2 protein by immunohistochemistry (Fig. 1C). Dou-
ble immunohistochemical (IHC) analysis of Olig2 expression in
NG2 cells of 18.5 days postcoitum (dpc) mouse brain showed
colocalization of Olig2 in NG2 cells with both stellate synanto-
cyte and bipolar progenitor morphologies (Fig. 1A). Quantita-
tive analysis of histological sections showed that 90% of NG2
cells were Olig2 in all subregions of the brain examined (dorsal
neocortex, corpus callosum, SVZVZ, and ventral forebrain
regions). In contrast, only 18% of the overall Olig2 cell
population on average expressed NG2. The number of Olig2
cells that expressed NG2 varied with the subregion of the brain
examined from a low of 8% in the SVZ to a high of 53% within
white matter tracts. We found that NG2 glial cells easily could
be distinguished from NG2Olig2 pericytes associated with
blood vessels (25) on the basis of morphology; however, we could
not entirely rule out that a minor population of NG2Olig2
cells in our counts are pericytes.
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Adult NG2 synantocytes have a highly differentiated mor-
phologic appearance with few similarities to myelinating oligo-
dendrocytes or their perinatal oligodendroglial progenitors. IHC
analysis of adult mouse and rat brain showed that at these later
stages of development 98% of NG2 cells coexpress Olig2;
however, NG2 cells remain a minority of the total Olig2 cell
population (Fig. 1B). As was found at 18.5 dpc, NG2Olig2
coexpressing cells were seen in all regions of the brain and in
NG2 cells with both synantocyte and progenitor morphology.
Examination of the Olig2 cell population showed that the
percentage of cells colabeled by NG2 varied again with the
subregions of the brain ranging from 6% in white matter tracts
to a high of 31% in the ventral forebrain.
These IHC findings were further validated by flow cytometry.
Analysis of freshly dissociated mouse dorsal neocortex at post-
natal day 1 (PN1), a period of rapid NG2 cell development, as
well as adult stages, confirmed that at least 90% of NG2 cells in
the postnatal period coexpress Olig2 (Fig. 2), even without
correction for the presence of NG2Olig2 pericytes within the
total NG2 cell population. Although only a minority of Olig2
cells coexpressed NG2 (31% in PN1 and 25% in adult), more
Olig2 cells were found to coexpress NG2 than in manual
counting procedures, possibly because of increased sensitivity of
flow cytometry compared with in situ IHC methods. Together,
these data show that almost all NG2 cells coexpress Olig2 at
prenatal, perinatal, and postnatal stages of development.
Olig Function Is Required for Early NG2 Cell Development in the
Brain. The earliest development of NG2 cells was observed at
14.5 dpc in the mouse CNS (7), so we next tested whether NG2
cell specification could occur in the absence of Olig2 function.
Analysis of the brains of Olig2/ mice at 14.5 dpc showed no
NG2 cells at this stage in mutants, whereas scattered cells were
readily noted in the developing cortex of heterozygous litter-
mates (Fig. 3A). To determine whether NG2 cell development
might bemerely delayed in the absence of Olig2 function, we also
examined mutant and heterozygous brains at 18.5 dpc (Fig. 3B),
the latest stage of development possible for Olig2/ mice.
Analysis of dorsal neocortex, corpus callosum, SVZ, and olfac-
tory bulb showed no evidence of NG2 cells with normal neural
morphology (Fig. 3B). Interestingly, within the ventral forebrain
in the region of the anterior commissure, rare NG2 cells of
unusual morphology (average of 6 cells per 16-m coronal
Fig. 1. NG2 cells express Olig2 in mouse brain. (A) Deconvolution images of
immunofluorescent staining showing NG2 (green Cy5) and Olig2 (red Cy2) are
coexpressed in neural cells with NG2 synantocyte and progenitor morphology
(white arrowheads) in normal 18.5 dpc mouse neocortex (cx), ventral fore-
brain (vfb), and developing white matter (iz). Olig2 cells (white arrowheads)
in the subventricular zone (svz) rarely expressed NG2. NG2 staining in pericytes
around blood vessels (white arrow in svz) served as internal control. Graph
shows summed results of manual cell counting at 18.5 dpc (2,949 total cells
counted; n  3 animals). (B) Double IHC staining for NG2 (red, alkaline
phosphatase) and Olig2 [brown, diaminobenzidine (DAB)] in adult rat brain.
Colocalization was seen in cells with complex synantocyte morphology (Up-
per) and cells with progenitor morphology (Lower) occurring as pairs of
recently divided cells. Graph shows summed results of manual cell counting
from adult mouse brain (578 total cells counted; n 2 animals). The percent-
age of Olig2 NG2 cells was 98% in all subregions of the adult brain.
Sections are hematoxylin counterstained. (C) Specificity testing of Olig2 mAb
TV37–1C10 in spinal cord white matter (red box in diagram) ofOlig2/mouse
at 18.5 dpc shows precise colocalization of signal from established rabbit
polyclonal anti-Olig2 antibody DF308 (red) with that from the mouse anti-
Olig2 antibody TV37–1C10 (green). Similar findings were obtained at embry-
onic and adult stages in brain (data not shown). Absence of any specific
labeling in Olig2/ mutant spinal cord (Lower) confirms specificity for Olig2.
Arrowhead marks autofluorescence in blood vessels (bv).
Fig. 2. Flow cytometry characterization of NG2 and Olig2 cell populations in
postnatal mouse brain. (A) Flow analysis of full thickness dorsal cortical mantle
from postnatal day 1 (PN1) mouse for NG2 (rabbit polyclonal; Chemicon) and
Olig2 (mouse monoclonal, TV37–1C10) (n  2 animals). (B) Flow analysis of
adult mouse dorsal neocortex for NG2 (rabbit polyclonal; Chemicon) and Olig2
(mouse monoclonal TV37–1C10) (n  2 animals). Note that, at both stages,
90% of NG2 cells are Olig2. Conversely, NG2 cells represent 31% of the
total Olig2 cell population.
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section of brain) were still detected (Fig. 3 B and C), suggesting
that NG2 cell development could be partially supported by
function ofOlig1. Indeed, these cells were in regions where small
populations of Olig2-independent OLPs were previously re-
ported to develop in Olig2/ mice (19). To test this possibility,
we thus analyzed Olig12/ compound mutants that lack any
evidence of OLP development (17). As indicated in Fig. 3C, no
cell bodies with recognizable synantocyte or bipolar morphology
were detectable in Olig12/ mutants. Together, these data
demonstrate that Olig function is required for NG2 cell speci-
fication in the forebrain, largely because of critical roles ofOlig2.
Olig2 Function Is Required for Spinal Cord NG2 Cell Development.
In the embryonic spinal cord, Olig activity is essential for
patterning of the ventral ‘‘pMN’’ domain (8–9.5 dpc), as well
as development of motor neurons (9–10.5 dpc) and an early wave
of oligodendrocytes (12.5 dpc) (23). At later stages, a dorsal
origin of oligodendrocytes has recently been reported in the fetus
(26–29). To determine whether dorsal or ventral spinal NG2 cell
development requires Olig function during the embryonic
andor fetal phases, we first investigated Olig2/ mutant spinal
cord at 18.5 dpc. As shown in Fig. 4A, no definitive NG2 cells
were observed in spinal cords of Olig2/ mice, in contrast to
heterozygotes, where NG2 cells were readily detected. Thus,
NG2 cells arising from both ventral and dorsal regions require
Olig function.
To further investigate the genetic requirement of Olig2 in
NG2 cell development, we introduced a bacterial artificial
chromosome (BAC) transgenic allele (OLIG2-BAC-Tg) that
carries the human OLIG2 and OLIG1 loci and partial regu-
latory sequences (30) into the Olig2/ line by intercross.
Expression of human OLIG2 in the Olig2/:OLIG2-BAC-Tg
line leads to rescue of OLP development (30), in light of the
fact that Olig1 is incapable of supporting OLP specification in
Olig2 null mutants (19). Concomitant with OLP rescue, we
noted effective production of NG2 cells with normal morphol-
ogy and distribution in the spinal cord of Olig2/:OLIG2-
BAC-Tg compound animals at all levels examined (Fig. 4B).
Together, these findings show that Olig2 activity is critical for
NG2 gliogenesis and indicate further developmental parallels
between OLPs and NG2 cells.
Discussion
Expanded Roles for Olig Genes in Neural Progenitor Cell Development.
Extensive analysis has shown critical roles for Olig basic helix–
loop–helix transcription factors in embryonic oligodendrocyte
development (17–19). Recent findings also suggest that Olig2
might have more general roles in other populations of neural
stemprogenitor cells, specifically radial glia and adult type C
progenitor cells of the SVZ (22, 26). NG2 cells are the most
prevalent cycling progenitors in the adult CNS and are the
primary responsive CNS cell type to neurological injury and
repair (11). Our data clearly link the bulk of the NG2 progenitor
Fig. 3. Olig genes are required for NG2 cell development in the brain. (A) IHC
for NG2 in 14.5 dpc mouse brain demonstrates the normal appearance
of multiprocessed NG2 cells in Olig2/ mice (black arrowheads) and their
absence in Olig2/ mice. NG2 staining in vessel pericytes is unaffected (red
arrowheads). (B) IHC at 18.5 dpc demonstrates complete loss of parenchymal
NG2 cells (black arrowheads) in the dorsal neocortex (cx), corpus callosum (cc),
subventricular zone (svz), and olfactory bulb (ob) of Olig2/ mice. Scattered
surviving cells were detected in the ventral forebrain (vfb; boxed
regions shown at higher power below). (C) The rare surviving NG2 cells in
Olig2/ ventral forebrain had abnormal morphology (black arrowheads).
However, analysis of ventral forebrain in Olig12/ mice showed complete
ablation of normal and abnormal appearing NG2 cells even within the ventral
forebrain.
Ligon et al. PNAS  May 16, 2006  vol. 103  no. 20  7855
N
EU
RO
SC
IE
N
CE
cell population to Olig2 expressing cell populations within the
CNS by demonstrating that NG2 cells express Olig2 and, more
importantly, that Olig2 is genetically required for NG2 cell
development in the embryonic and perinatal stages. Given the
diverse functions associated with NG2 cells in the literature,
these studies expand the potential roles of Olig genes in main-
tenance of neurologic function and pathological states such as
CNS injury (11) and brain tumors (24) where NG2 cells have
been suggested to have important roles.
Olig2 Expression in NG2 Synantocytes Supports a Lineage Connection
to Oligodendroglia.Our findings demonstrate90% of NG2 cells
express Olig2, a pan-oligodendroglial cell type marker within the
neonatal and adult rodent brain (24). Given that NG2 cells
express other oligodendroglial markers including Olig1,
PDGFR, O4, and PLP (7), our findings provide further evi-
dence for the relationship of NG2 cells to OLPs. The finding that
only 1% of NG2 cells in the adult brain express the oligoden-
droglial marker tetraspanin (CD9) has been used to argue that
NG2 cells comprise a fourth neuroepithelial lineage (31). How-
ever, we find that CD9 marks only a minority (1%) of Olig2
cells at 18.5 dpc, whereas more established OLP markers, such
as PDGFR, overlap with Olig2 to a much higher degree (K.L.L.
and D.H.R., unpublished observations), consistent with the
possibility that CD9 grossly under reports OLP numbers. Thus,
our expression analysis suggests that the vast majority of ante-
natal and postnatal parenchymal NG2 cells express Olig2 and
other oligodendroglial markers.
Our analyses were in good agreement with previous studies
showing NG2 coexpression with PDGFR (1), and studies that
suggest NG2 cells are a relatively small subpopulation of Olig2
cells. For example, Buffo et al. (11) recently reported that NG2
cells are 30% of the total Olig2 cell population in the adult
brain. The cell types most likely contributing to the
Olig2NG2 population are newly specified premyelinating
OLPs, myelinating oligodendrocyte, radial glia, and type C cells.
Another minor population of Olig2, GFAP, NG2 cells has
also been reported at P7 (32).
Although most NG2 cells definitively coexpress Olig2, rare
cells were noted that were NG2 but were not convincingly
associated with nuclear Olig2 staining. These cells were scored
as NG2Olig2 for purposes of our study but often had a
morphology that was difficult to reliably distinguish from ex-
pression of NG2 within pericytes around blood vessels, suggest-
ing that the percentage of cells that are NG2Olig2 may in
reality be even lower than those we have reported. Further
analysis using additional techniques to analyze such potentially
small cell populations would be necessary to characterize the
nature of these cells and to determine whether they might have
unique functions.
Olig Function Is Necessary for Development of NG2-Positive Synan-
tocytes. We asked whether bipolar NG2 cells andor synanto-
cytes could develop independently of the oligodendrocyte lin-
eage by analysis of Olig null mutants from 14.5 to 18.5 dpc. Our
data demonstrate that Olig gene function is necessary for NG2
cell development throughout the CNS at antenatal stages.
Although this result does not prove the existence of a uniform
lineage, it establishes a common genetic requirement for Olig
function within glial precursors for OLPs and NG2 cells, includ-
ing both bipolar NG2OLPs and synantocytes. In summary, our
results, coupled with previous findings, suggest that prenatal
OLPs can assume at least two distinct fates: myelinating oligo-
dendrocytes or synantocytes. This idea is supported by two lines
of evidence: (i) OLPs and synantocytes are immunophenotypi-
cally identical in that there are no markers specific to synanto-
cytes, and (ii) our functional data indicate that both cells derive
from an Olig2 precursor.
An independent function for Olig2 in glial subtype determi-
nation has been suggested, based on the ability of Olig2 to
suppress the astrocyte fate in cultures of spinal cord progenitors
established after motoneuron differentiation is no longer occur-
ring (33). Such in vitro data do not address the issue of secondary
effects of the early patterning defects on oligodendrogenesis that
occur in Olig mutants in vivo. Although the OLIG2-BAC-Tg
transgene lacks regulatory elements for expression of OLIG2 at
early stages of neural tube formation, and therefore fails to
rescue the normal patterning of the pMN domain (30), we found
that expression from this line rescues the OLPNG2 develop-
mental defect inOlig2/mice. These data therefore suggest that
Olig2 is required for NG2 fate specification, independently of its
role in neural tube patterning.
NG2 cells have been proposed to be the in vivo correlate of O2A
Fig. 4. Olig2 function is necessary and sufficient for NG2 cell development
in the spinal cord. (A) IHC staining for Olig2 and NG2 in 18.5 dpc Olig2/
and Olig2/ mouse cervical spinal cord. No cells with NG2 morphology
were detected in the absence of Olig2 expression and function. (B) Diagram
of 116-kB human BAC clone 2401C4 containing OLIG1 and OLIG2 loci.
Crossing of a transgenic mouse line containing this BAC (OLIG2-BAC-Tg)
into the Olig2/ mouse line rescues appropriate expression of OLIG2 and
promotes OLP development at 18.5 dpc mouse in the spinal cord (30).
Concomitant with OLP rescue, NG2 cells with complex morphology were
identified (black arrowhead).
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glial-restricted progenitors, which, under in vitro culture conditions,
can give rise to oligodendrocytes and type II astrocytes. One
possibility, therefore, is that Olig function is only required within
NG2 cells to suppress their astrocytic potential and promote their
later development into oligodendrocytes. If so, developmental
analysis ofOlig-null mutants would be expected to show little to no
effects on NG2 cell specification or development, but would
exhibit compromised potential of NG2 cells to become OLPs. In
fact, we found a failure to produce any parenchymal NG2 cells,
suggesting that Olig function is required for initial NG2 cell
development per se. Although our data do not definitively distin-
guish whetherOlig2 is required to specify ormaintain an early NG2
population, given the known functions of Olig2 in specification of
the oligodendrocyte lineage, we speculate that Olig2 is also re-
quired for specification of NG2 cells. Further, our results do not
establish a function for Olig2 in regulation of NG2 expression.
Our findings suggest the possibility that postnatal NG2 pro-
genitor cell development may also depend on Olig function.
Although recent work has shown that Olig1 function is dispens-
able for NG2 cell development in the adult neocortex (20, 21),
this finding would still be consistent with our observations of
nearly or totally absent NG2 cell development in Olig2 and
Olig12 null mutants, respectively. Because Olig2 mutants die at
birth, we were unable to determine the later roles for Olig2 in
adult progenitor populations. However, this important issue
could be further addressed by using conditional knockout ap-
proaches. Additionally, our work suggests that use of transgenic
mouse lines with a targetedOlig2 locus (i.e.,Olig2-cre) may allow
determination of the in vivo fate of postnatal NG2 cells and may
be used as a molecular handle to address the role Olig2NG2
progenitors play in the setting of brain injury and brain cancer.
Materials and Methods
Transgenic Mice. Mice that carry targeted mutations of the Olig2
and Olig12 loci have been described in refs. 17 and 19. Het-
erozygous Olig2 mutant mice that were hemizygous for two
copies of a human BAC transgene encompassing the OLIG1 and
OLIG2 locus on chromosome 21 (line #34) (30) were sibling-
mated to generate homozygous Olig2/:BAC-Tg/ and het-
erozygous Olig2/:BAC-Tg/ offspring. Genotypes were deter-
mined by PCR on tail-tip DNA. To evaluate OLP and NG2 cell
rescue, two animals of each genotype were analyzed.
Production of Olig Monoclonal Antibody TV371C10. A GST-fusion
protein containing the amino-terminal 108 amino acids of
murineOlig2 was injected intomice by theMonoclonal Antibody
Core (Dana-Farber Cancer Institute, Boston). At 8 weeks after
the initial injection of antigen, the spleen was harvested to
produce hybridomas, and these hybridomas were screened for
reactivity to Olig2 by immunoblot and immunostaining. This
procedure identified the subclone TV37–1C10 as having specific
and effective activity.
Tissue Preparation and IHC. Mouse embryos were collected at
different ages according to the assumption that mating occurred at
midnight with plug detection at the following noon (0.5 dpc).
Embryos were fixed in 4% paraformaldehyde (PFA) in PBS (pH
7.0), whereas adult mice and rats were cardiac perfused with 4%
PFA, and the brain was harvested and further fixed in PFA for 24 h.
All tissues were washed in 0.5 M sucrose overnight and embedded
in optimal cutting temperature (OCT) compound for cryosection-
ing at 16 m.
IHC was performed on cryosections using the following
primary antibodies: (i) for immunofluorescence, monoclonal
guinea pig anti-NG2 (gift of W. Stallcup, Burnham Institute, La
Jolla, CA) and polyclonal rabbit anti-Olig2 (DF308; ref. 24); (ii)
for diaminobenzidine (DAB), brightfield staining polyclonal
rabbit anti-NG2 (Chemicon; AB5320); (iii) for brightfield, dou-
ble staining polyclonal rabbit anti-NG2 (Chemicon; AB5320)
was combined with mouse monoclonal anti-Olig2 (TV73–1C10)
for all counts except for one adult brain, which used rabbit
polyclonal anti-Olig2 (DF308). Identical results were obtained
regardless of the Olig2 antibody used. Rabbit on rabbit combi-
nation of antibody was performed sequentially and with inacti-
vation of the first primary antibody before application of the
second primary antibody. DAB brightfield IHC was performed
by using the Envision and Envision Doublestain Systems
(DAKO; K4011, K1395) according to the manufacturer’s in-
structions. Double IHC staining was detected by using horse-
radish peroxidase-DAB reaction and AP-Fast Red reaction. All
IHCs were performed by using heat antigen retrieval.
Cell Counting.Expression analysis of NG2 andOlig2 was performed
by using multiple techniques for cross validation of results. To
achieve more precise colocalization information, immunofluores-
cent analysis was performed by using deconvolution microscopy
and three-dimensional reconstruction of image stacks for manual
cell counting and accurate distinction of NG2 staining in pericytes
from neural cells with processes. Pericytes were identified based on
morphology alone, because positive identification by colabeling
with antibody against PDGFR (Santa Cruz Biotechnology; sc-
432) was technically unsuccessful in our hands. Immunofluorescent
analysis was performed at the rostral and medial forebrain levels at
several subregions (n  1). To better evaluate the total NG2
population, quantitation was also performed by using the more
sensitive technique of double brightfield IHC.Manual cell counting
was done at rostral and medial forebrain levels in normal mouse
brains from 18.5 dpc and adult (n  2 animals each). Data from
fluorescent and brightfield methods at 18.5 dpc were summed for
purposes of reporting.
Mouse Brain Dissociation. Normal C57BL6J postnatal day 1 dorsal
cortical mantle (full thickness) and adult mouse dorsal neocortex
(all layers, but excluding subcortical structures) were dissected by
using a dissectingmicroscope and placed inDMEMsolution on ice.
Tissue was washed in artificial cerebrospinal fluid (aCSF) and
acutely dissociated as described (34), with modification in tissue
dissociation medium-collagenase IV (1 mgml; Worthington), hy-
aluronidase (0.67 mgml; Sigma), DNase I (0.4 mgml; Worthing-
ton), and kynurenic acid and N-acetylcysteine (60 gml; Sigma).
Cells were washed and stained in the fresh state for FACS analysis.
Trypsin was avoided because of higher proteolytic activity and
potential cleavage of cell surface proteins (35).
Flow Cytometry. Fluorescent activated cytometry was performed on
a FACSCalibur machine (BD Biosciences). Antibodies included:
mouse anti-Olig2 (TV37–1C10) and polyclonal rabbit anti-NG2
(Chemicon; AB5320). Cells were first stained for surface NG2
(antibody dilution 1:100) for 30 min at 4°C and then washed, fixed,
and permeabilized to allow access to intracellular antigens (Cyto-
fixCytoperm solution; BD Biosciences; no. 554714). Cells were
then further incubated with Olig2 antibody (dilution 1:100) for 30
min at 4°C and washed. Cells were incubated with secondary
antibodies (anti-rabbit Alexa488 and anti-mouse Cy5; Molecular
Probes) for 30 min at 4°C and washed before FACS analysis. Single
positives and isotype stains were used as controls for compensation
and gating thresholds. Data were analyzed by using FLOWJO soft-
ware v6.2.1 (Tree Star, Ashland, OR).
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